AstraZeneca PLC
LSE:AZN

Watchlist Manager
AstraZeneca PLC Logo
AstraZeneca PLC
LSE:AZN
Watchlist
Price: 10 256 GBX 0.12% Market Closed
Market Cap: 159B GBX
Have any thoughts about
AstraZeneca PLC?
Write Note

AstraZeneca PLC
Total Current Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

AstraZeneca PLC
Total Current Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Current Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
AstraZeneca PLC
LSE:AZN
Total Current Liabilities
$28.6B
CAGR 3-Years
9%
CAGR 5-Years
12%
CAGR 10-Years
6%
GlaxoSmithKline PLC
LSE:GSK
Total Current Liabilities
ÂŁ20.3B
CAGR 3-Years
-2%
CAGR 5-Years
-5%
CAGR 10-Years
5%
Verona Pharma PLC
NASDAQ:VRNA
Total Current Liabilities
$28m
CAGR 3-Years
0%
CAGR 5-Years
13%
CAGR 10-Years
N/A
Indivior PLC
LSE:INDV
Total Current Liabilities
$1B
CAGR 3-Years
17%
CAGR 5-Years
9%
CAGR 10-Years
8%
Hikma Pharmaceuticals PLC
LSE:HIK
Total Current Liabilities
$1.4B
CAGR 3-Years
13%
CAGR 5-Years
1%
CAGR 10-Years
9%
Dechra Pharmaceuticals PLC
LSE:DPH
Total Current Liabilities
ÂŁ164m
CAGR 3-Years
6%
CAGR 5-Years
12%
CAGR 10-Years
5%
No Stocks Found

AstraZeneca PLC
Glance View

Market Cap
159B GBX
Industry
Pharmaceuticals

AstraZeneca PLC stands as a formidable entity in the global pharmaceutical landscape, adeptly navigating the intricate dance of innovation and commerce. Emerging from a merger between Sweden's Astra AB and the UK's Zeneca Group in 1999, the company has carved a niche through its relentless pursuit of cutting-edge medical solutions. Central to its operations is a sophisticated ecosystem of research and development, where thousands of scientists tirelessly explore the expansive frontier of biotechnology. The lifeblood of AstraZeneca's growth is its robust pipeline, where potential life-saving medicines traverse an arduous journey from laboratory benches to clinical trials, and eventually, regulatory approval. This rigorous process underscores its commitment to addressing complex diseases in areas such as oncology, cardiovascular, and respiratory health – domains marked by high unmet medical needs and significant market demand. The commercial prowess of AstraZeneca is equally vital to its success narrative. With a global reach spanning over 100 countries, the company leverages its advanced production facilities and strategic partnerships to deliver its pharmaceutical breakthroughs to those in need. Revenue generation is predominantly through the sale of prescription drugs, with blockbuster medications serving as pivotal financial pillars. These products, once approved, are strategically marketed to healthcare providers, ensuring they gain traction in various markets. AstraZeneca's approach is finely tuned to balance the scale of mass production with the nuance of catering to specific regional demands, maintaining a competitive edge in a crowded pharmaceutical landscape. Through these intricacies of innovation, production, and strategic market positioning, AstraZeneca not only generates substantial revenues but also reinforces its mission to improve patient health outcomes worldwide.

AZN Intrinsic Value
14 313.88 GBX
Undervaluation 28%
Intrinsic Value
Price

See Also

What is AstraZeneca PLC's Total Current Liabilities?
Total Current Liabilities
28.6B USD

Based on the financial report for Jun 30, 2024, AstraZeneca PLC's Total Current Liabilities amounts to 28.6B USD.

What is AstraZeneca PLC's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 10Y
6%

Over the last year, the Total Current Liabilities growth was 8%. The average annual Total Current Liabilities growth rates for AstraZeneca PLC have been 9% over the past three years , 12% over the past five years , and 6% over the past ten years .

Back to Top